Cardiovascular disease remains the leading cause of death in the United States, with coronary heart disease affecting approximately 20-21 million adults, nearly 795,000 strokes occurring annually, and an estimated 8-10 million individuals living with peripheral artery disease. For these populations, antiplatelet therapy is a foundational tool for secondary prevention of arterial thrombotic events, including myocardial infarction, ischemic stroke, and PAD complications. Appropriate agent selection, therapy duration, and de-escalation decisions directly determine whether patients benefit from ischemic protection or face preventable bleeding-related hospitalizations.
AAVBC's Antiplatelet Therapy Utilization Management Quick Reference Guide equips clinicians and care teams with a comprehensive, evidence-aligned reference covering indication criteria, single and dual antiplatelet therapy selection, DAPT duration frameworks, bleeding and ischemic risk stratification, drug interaction considerations, special population guidance, and transition of care standards. Grounded in current ACC, AHA, ASA, and SCAI guidelines, this guide supports consistent, individualized clinical decision-making, helping care teams align antiplatelet therapy with each patient's evolving risk profile, with the documentation rigor and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of antiplatelet therapy utilization — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of antiplatelet therapies, and provide care teams with the necessary strategies to thrive within a value-based framework.
Cardiovascular disease remains the leading cause of death in the United States, with coronary heart disease affecting approximately 20-21 million adults, nearly 795,000 strokes occurring annually, and an estimated 8-10 million individuals living with peripheral artery disease. For these populations, antiplatelet therapy is a foundational tool for secondary prevention of arterial thrombotic events, including myocardial infarction, ischemic stroke, and PAD complications. Appropriate agent selection, therapy duration, and de-escalation decisions directly determine whether patients benefit from ischemic protection or face preventable bleeding-related hospitalizations.
AAVBC's Antiplatelet Therapy Utilization Management Quick Reference Guide equips clinicians and care teams with a comprehensive, evidence-aligned reference covering indication criteria, single and dual antiplatelet therapy selection, DAPT duration frameworks, bleeding and ischemic risk stratification, drug interaction considerations, special population guidance, and transition of care standards. Grounded in current ACC, AHA, ASA, and SCAI guidelines, this guide supports consistent, individualized clinical decision-making, helping care teams align antiplatelet therapy with each patient's evolving risk profile, with the documentation rigor and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of antiplatelet therapy utilization — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of antiplatelet therapies, and provide care teams with the necessary strategies to thrive within a value-based framework.
